AU2017383537B2 - Methods of treatment with anti-Factor XI/XIa antibodies - Google Patents

Methods of treatment with anti-Factor XI/XIa antibodies Download PDF

Info

Publication number
AU2017383537B2
AU2017383537B2 AU2017383537A AU2017383537A AU2017383537B2 AU 2017383537 B2 AU2017383537 B2 AU 2017383537B2 AU 2017383537 A AU2017383537 A AU 2017383537A AU 2017383537 A AU2017383537 A AU 2017383537A AU 2017383537 B2 AU2017383537 B2 AU 2017383537B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017383537A
Other languages
English (en)
Other versions
AU2017383537A1 (en
Inventor
Carola Friedman
Yasser Khder
Martin Lefkowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2017383537A1 publication Critical patent/AU2017383537A1/en
Application granted granted Critical
Publication of AU2017383537B2 publication Critical patent/AU2017383537B2/en
Priority to AU2024287181A priority Critical patent/AU2024287181A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2017383537A 2016-12-23 2017-12-22 Methods of treatment with anti-Factor XI/XIa antibodies Active AU2017383537B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024287181A AU2024287181A1 (en) 2016-12-23 2024-12-23 Methods of treatment with anti-Factor XI/XIa antibodies

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662438654P 2016-12-23 2016-12-23
US62/438,654 2016-12-23
US201762589851P 2017-11-22 2017-11-22
US62/589,851 2017-11-22
PCT/IB2017/058345 WO2018116267A2 (en) 2016-12-23 2017-12-22 Methods of treatment with anti-factor xi/xia antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024287181A Division AU2024287181A1 (en) 2016-12-23 2024-12-23 Methods of treatment with anti-Factor XI/XIa antibodies

Publications (2)

Publication Number Publication Date
AU2017383537A1 AU2017383537A1 (en) 2019-06-27
AU2017383537B2 true AU2017383537B2 (en) 2024-10-03

Family

ID=61022382

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017383537A Active AU2017383537B2 (en) 2016-12-23 2017-12-22 Methods of treatment with anti-Factor XI/XIa antibodies
AU2024287181A Pending AU2024287181A1 (en) 2016-12-23 2024-12-23 Methods of treatment with anti-Factor XI/XIa antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024287181A Pending AU2024287181A1 (en) 2016-12-23 2024-12-23 Methods of treatment with anti-Factor XI/XIa antibodies

Country Status (9)

Country Link
US (3) US20200231701A1 (enExample)
EP (1) EP3558370A2 (enExample)
JP (3) JP7110199B2 (enExample)
KR (2) KR102702288B1 (enExample)
CN (2) CN118320078A (enExample)
AU (2) AU2017383537B2 (enExample)
CA (1) CA3048157A1 (enExample)
IL (2) IL267519B2 (enExample)
WO (1) WO2018116267A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9982061B2 (en) 2014-10-01 2018-05-29 Medimmune Limited Antibodies to ticagrelor and methods of use
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
AU2017383232B2 (en) 2016-12-23 2024-09-12 Novartis Ag Factor XI antibodies and methods of use
US20200231701A1 (en) * 2016-12-23 2020-07-23 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
KR102880762B1 (ko) * 2018-09-20 2025-11-03 에스에프제이 파마 엑스, 인코포레이티드 티카그렐러 활성을 반전시키는 방법
CN113474374B (zh) * 2019-04-16 2025-05-02 四川科伦博泰生物医药股份有限公司 抗FXI/FXIa抗体及其用途
CN110423278B (zh) 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
BR112022012064A2 (pt) * 2019-12-20 2022-08-30 Anthos Therapeutics Inc Formulação de distribuição de fármaco intravenosa, frasco compreendendo a mesma e método de tratamento de um sujeito acometido por ou em risco de desenvolver um distúrbio tromboembólico
TW202405022A (zh) * 2022-06-24 2024-02-01 美商安瑟斯治療公司 與抗因子ｘｉ／因子ｘｉａ抗體之組合療法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
AU643109B2 (en) 1990-12-14 1993-11-04 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
AU3382595A (en) 1994-07-29 1996-03-04 Smithkline Beecham Corporation Novel compounds
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US20030235587A1 (en) * 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20070190059A1 (en) * 1996-01-17 2007-08-16 Smithkline Beecham Corporation Antithrombotic agents
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
AU766551C (en) * 1998-08-28 2005-02-17 Genentech Inc. Human anti-factor IX/IXa antibodies
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
CA2411369A1 (en) * 2000-05-15 2001-11-22 Smithkline Beecham Corporation Antithrombotic agents
AU2008326348B2 (en) * 2007-11-21 2014-01-30 Oregon Health & Science University Anti-factor XI monoclonal antibodies and methods of use thereof
HUE041556T2 (hu) * 2008-06-19 2019-05-28 Prothix Bv XI-es faktor elleni ellenanyagok alkalmazása vérrögképzõdés megelõzésére vagy kezelésére
AU2009335643B2 (en) * 2008-12-18 2014-05-29 Oregon Health & Science University Anti-fXI antibodies and methods of use
IL212911A0 (en) * 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof
SI2847228T1 (sl) * 2012-05-10 2018-11-30 Bayer Pharma Aktiengesellschaft Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
US20200231701A1 (en) 2016-12-23 2020-07-23 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies

Also Published As

Publication number Publication date
JP2022141831A (ja) 2022-09-29
KR20240134248A (ko) 2024-09-06
JP2024116221A (ja) 2024-08-27
AU2017383537A1 (en) 2019-06-27
EP3558370A2 (en) 2019-10-30
IL267519A (en) 2019-08-29
AU2024287181A1 (en) 2025-03-06
CN110325211A (zh) 2019-10-11
KR102702288B1 (ko) 2024-09-05
KR20190099256A (ko) 2019-08-26
IL267519B1 (en) 2024-12-01
JP2020504110A (ja) 2020-02-06
CA3048157A1 (en) 2018-06-28
US20200231701A1 (en) 2020-07-23
IL316673A (en) 2024-12-01
JP7110199B2 (ja) 2022-08-01
JP7500662B2 (ja) 2024-06-17
WO2018116267A3 (en) 2018-08-02
WO2018116267A2 (en) 2018-06-28
CN118320078A (zh) 2024-07-12
US20250197522A1 (en) 2025-06-19
IL267519B2 (en) 2025-04-01
US20230002507A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
AU2021273615B2 (en) Factor XI antibodies and methods of use
AU2017383537B2 (en) Methods of treatment with anti-Factor XI/XIa antibodies
AU2017383232B2 (en) Factor XI antibodies and methods of use
RU2847356C2 (ru) Антитела к фактору xi и способы их применения

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)